ASCO Publishes Two Independent Research Programs from Malecare
Malecare not only is the world’s largest prostate cancer support and education organization it also is responsible for prostate cancer research which has been recognized and published by the world’s largest organization of oncologists, the [...]
Myriad Genetics Attempts To Deny Patients Their Personal Genetic Information
In 2013, Myriad Genetic failed – in a case that was heard in the United States Supreme Court - to patent the BRCA1 and BRCA2 genes. We all have these two genes which, when they [...]
Understanding the Complexity of Prostate Cancer Drug Names – Cutting Through The Confusion
As drugs are developed they are given many different names, but the drug (or treatment) is the same despite its name. For us laymen, multiple names for the same drug is confusing. So, why are [...]
From Active Surveillance to Metastatic Prostate Cancer – Know The Risks As You Decide
Historically, too many men were haphazardly treated for prostate cancer. Happily, the incidents of over treatment have been declining and the general acceptance of Active Surveillance has emerged as the preferred management strategy for men [...]
Good News, The House Appropriations Committee Increases the Ask For The DoD PCRP Allocation for FY 2017
Today, I have some good news to share with you. Malecare, along with many other prostate cancer advocacy groups have been hard at work attempting to persuade members of Congress to not only maintain the [...]
Genetic Biomarker Predicts Peripheral Neuropathy Associated With Docetaxel Chemotherapy For Prostate Cancer
According to researchers at the H. Lee Moffitt Cancer Center & Research Institute, men with a mutation in their VAC14 gene are more susceptible to Docetaxil chemotherapy induced neuropathy and nerve pain. This debilitating side [...]